ReviewHealth science reports2026
The Economic Burden of Gastric Cancer: A Systematic Review.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.Journal of clinical medicine · 2026Review
- Synthesis and In Vitro Anticancer Activity of New Acridone Derivatives: Computational DFT and Molecular Docking Studies.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gastric cancer is the fifth most common cancer, as well as the fourth leading cause of cancer-related mortality. It significantly burdens patients, families, and the healthcare system. Considering this large economic impact, this review study aims to evaluate the total economic burden of gastric cancer. Methods: An extensive search was conducted in PubMed, Web of Science, ScienceDirect, Scopus, and ProQuest databases for all original research articles that evaluated/reported the economic burden of gastric cancer. No timing restrictions and studies up to December 2024 were included. The inclusion criteria were defined using the PICOTS model, and the quality of the selected studies was assessed using the Drummond checklist by two independent researchers. Data from each study were extracted using a standardized data extraction form. Results: The cost data originated from 17 studies of gastric cancer. Most of the studies were performed in Asia, and the societal perspective was the most common approach for cost measurement. Direct medical costs would represent the most significant component of the economic burden of gastric cancer, the authors found. Chemotherapy was the dominant cost factor among these. In addition, indirect costs included a significant share of non-medical costs, such as travel, lodging, and home care. These included indirect productivity loss above due to absenteeism, premature mortality, and time costs. Conclusion: This review consolidates evidence that the economic burden of gastric cancer is multifaceted and substantial, driven predominantly by direct medical costs like chemotherapy but significantly amplified by indirect productivity losses. The variation in healthcare systems and stage at diagnosis are critical factors shaping this economic impact, underscoring the potential for early detection and tailored economic interventions to mitigate this burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.